Sirolimus-Eluting Balloons Show Promise as Alternative to Permanent Stents in Heart Attack Treatment
Key Insights
A new sub-study from the SELUTION DeNovo trial demonstrates that sirolimus-eluting balloons (SEB) can safely reduce the need for permanent stents in patients with non-ST-elevation myocardial infarction (search) and unstable angina (search).
The study analyzed 1,089 patients and found similar one-year outcomes between SEB with minimal stenting and traditional drug-eluting stents, with target vessel failure rates of 5.3% versus 4.9% respectively.
This "Leave-Nothing-Behind" strategy potentially reduces long-term complications associated with permanent metal implants, which affect 1-4% of patients annually.
A groundbreaking sub-study suggests that sirolimus-eluting balloons (SEB) could revolutionize treatment for certain heart attacks by reducing reliance on permanent stents while maintaining safety and efficacy. The research, presented at the Society for Cardiovascular Angiography & Interventions (search) (SCAI) 2026 Scientific Sessions in Montreal, offers new hope for patients with acute coronary syndrome (search).
Novel Approach Addresses Stent-Related Complications
Acute Coronary Syndrome (search) (ACS) occurs when blood flow to the heart is suddenly reduced, putting the heart muscle at risk. ACS often leads to Non-ST-Elevation Myocardial Infarction (search) (NSTEMI), which accounts for 70% of heart attacks. Most of these patients undergo percutaneous coronary intervention (PCI), or an angioplasty, to restore blood flow.
Currently, during PCI, cardiologists use drug-eluting stents (DES) - tiny metal mesh tubes that keep arteries permanently open. However, studies have shown that there is a 1 to 4% annual rate of complications due to the permanent presence of metal in the artery.
The SELUTION Drug Eluting Balloon (search) represents a paradigm shift with its "Leave-Nothing-Behind" strategy. This drug-coated balloon delivers medication directly to the artery wall without leaving a stent behind, potentially reducing long-term complications related to permanent implants.
Promising Clinical Trial Results
The SELUTION DeNovo study is a prospective, randomized, open-label, multicenter, non-inferiority trial comparing DES to SEB in "all comers." This pre-specified sub-study analyzed 1,089 patients with NSTEMI or unstable angina (search) to assess one-year heart-related problems.
Patients were divided into two treatment arms: one receiving implantation of DES and another undergoing placement of SELUTION SLR™ SEB (Cordis) with provisional stenting.
The results demonstrated comparable safety and efficacy between the two approaches. At one year, the rates of target vessel failure (TVF) were remarkably similar at 5.3% for SEB versus 4.9% for DES. Cardiac death rates were equally low in both groups, with 0.6% in the SEB group compared to 0.8% in the DES group.
Additional outcome measures reinforced these findings. Target-vessel related myocardial infarction rates were 3.1% for SEB and 2.8% for DES, while clinically-driven target vessel revascularization rates were 3.1% and 2.7% respectively.
Clinical Implications and Future Directions
"For many years, stents were the standard approach for these patients, but this study shows that we don't always need to leave a permanent implant behind," explained Christian Spaulding, MD, PhD, FACC, FESC, professor of cardiology at Paris Descartes University (search) in Paris, France. "Using a selective drug-coated balloon strategy allows us to treat the blockage effectively while preserving the artery's natural structure, giving clinicians more flexibility for future treatments."
The sub-study's findings support the use of SEB with minimal stenting as a safe and effective alternative to DES for patients with NSTEMI or unstable angina (search). This approach could particularly benefit patients who may require future interventions, as it preserves the natural arterial architecture.
However, the authors note that potential benefits of minimal stenting will require longer-term evaluation, including five-year outcomes, to fully establish the long-term advantages of this innovative treatment strategy.
The research represents a significant advancement in interventional cardiology, offering clinicians a new tool that balances immediate therapeutic needs with long-term patient outcomes while potentially reducing the burden of permanent implants.